Feature Story | 1-Apr-2005

Cesium capsules hit cancer harder

DOE/Pacific Northwest National Laboratory



A shorter half-life and cesium radiation promise to make cesium-131 capsules harder on cancer and easier on the patient.

Developed by IsoRay Medical, Inc., with assistance from Pacific Northwest National Laboratory, this new FDA-approved treatment uses tiny capsules or seeds filled with a small dose of the radioactive isotope, cesium-131.

The capsules are implanted near or in the cancerous tumor, where x-rays emitted by the cesium damage the genetic material of the cancer cells, making it impossible for these cells to continue to grow and divide. With cesium-based brachytherapy (from the Greek prefix "brachy," meaning "close"), more power or dose is delivered to the tumor over a shorter time.

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.